CA
NZ
UK
AU
IND
US
Zevra Therapeutics (NASDAQ:ZVRA) sells MIPLYFFA for Niemann-Pick disease type C. The screener listsReturn on Equityof 33.44%,Operating Marginof 28.71%, debt to equity of 0.01 and trailing revenue growth of 119.40%. Reported figures are lower: second quarter revenue grew about 53% and first half revenue was …
Intellia Therapeutics rose without a verified trigger; the nearest items were a Barclays Sell initiation with a USD 8 target on October 6 and a Wells Fargo Hold with a USD 15 target on October 2, both from an aggregator. The anchor is lonvo-z, …
YD Bio (NASDAQ:YDES) is an ophthalmology and diagnostics company with no approved products. YD Bio traded between USD 3.19 and USD 4.25 through most of September 2026, then closed at USD 3.23 on September 23. A 47.7% jump followed on September 24, and closes …
● Non-GAAPNet Incomereached $371.1 million, or $2.24 per diluted share.
Haemonetics furnished an 8-K on October 8, 2026 under its Regulation FD item. It recalled the supply agreement with CSL Plasma, first disclosed on August 18, 2026, that lets CSL use Haemonetics NexSys PCS devices with Persona PLUS technology and buy related disposables in …
The screener listsReturn on Equityof 33.44%,Operating Marginof 28.71%, debt to equity of 0.01 and trailing revenue growth of 119.40%. Reported figures are lower: second quarter revenue grew about 53% and first half revenue was USD 75.9 million against USD 46.3 million, about 64% higher …
YD Bio traded between USD 3.19 and USD 4.25 through most of September 2026, then closed at USD 3.23 on September 23. A 47.7% jump followed on September 24, and closes of USD 5.73, USD 7.11, USD 7.61, USD 7.42 and USD 7.81 followed …
The screener splits healthcare into health technology, which typically covers drug makers, biotechs and devices, and health services, which typically covers insurers and care providers. Health technology is last of 20 sectors on median one-week return, and Consumer Durables is next at negative 1.31%, …
Arbutus Biopharma (NASDAQ:ABUS) develops hepatitis B treatments and licenses lipid nanoparticle patents to Genevant, a company in which it owns about 16%. On March 3, 2026 Arbutus and Genevant settledPatentlitigation with Moderna. Moderna agreed to pay USD 950 million upfront, paid in July 2026, …
Myriad was downgraded to Underweight from Overweight at Piper Sandler with a USD 2 target in early September 2026, and UBS assumed coverage with a Neutral rating and a USD 3.60 target around September 9. Stephens had earlier cut its target to USD 3 …
Please wait processing your request...